Most Liquid Biotechnology Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1GMAB Genmab AS
21.61 B
(0.11)
 2.10 
(0.23)
2ABBV AbbVie Inc
11.88 B
 0.38 
 0.89 
 0.34 
3AMGN Amgen Inc
11.48 B
 0.02 
 1.39 
 0.03 
4VRTX Vertex Pharmaceuticals
9.77 B
 0.16 
 2.03 
 0.32 
5BNTX BioNTech SE
9.33 B
(0.08)
 2.18 
(0.17)
6MRNA Moderna
8.35 B
 0.08 
 3.94 
 0.31 
7REGN Regeneron Pharmaceuticals
7.02 B
 0.25 
 1.11 
 0.27 
8GILD Gilead Sciences
6.14 B
(0.06)
 1.83 
(0.11)
9BGNE BeiGene
5.7 B
(0.03)
 3.30 
(0.10)
10BIIB Biogen Inc
4.91 B
(0.05)
 1.70 
(0.08)
11GLPG Galapagos NV ADR
4.43 B
(0.08)
 1.72 
(0.13)
12IMAB I Mab
3.92 B
 0.07 
 6.27 
 0.44 
13INCY Incyte
2.72 B
 0.06 
 2.03 
 0.12 
14ARGX Argenx NV ADR
2.6 B
(0.06)
 3.86 
(0.23)
15ALNY Alnylam Pharmaceuticals
2.27 B
(0.05)
 2.61 
(0.14)
16UTHR United Therapeutics
2.26 B
(0.05)
 1.63 
(0.09)
17VIR Vir Biotechnology
2.2 B
 0.09 
 3.59 
 0.33 
18SRPT Sarepta Therapeutics
2.07 B
 0.22 
 3.26 
 0.71 
19CRSP Crispr Therapeutics AG
2.07 B
 0.09 
 4.06 
 0.38 
20IONS Ionis Pharmaceuticals
2.04 B
(0.09)
 2.17 
(0.19)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).